EB Clinet Conference 2024 from October 17th to 18th, 2024 in Vienna, Austria
IWC (Interdisciplinary Wound Congress) on 28th of November, 2024 in Cologne, Germany
7th Nuremberg Wound Congress from December 5th to 6th, 2024 in Nuremberg, Germany
4th WundD.A.CH three-country congress from 23rd to 24th of June 2025 in Freiburg
For the press release click here
The article outlines that this is Argentina's first study involving stem cell therapy, marking a significant milestone for the country. It also highlights the treatment of the first patient and informs that they plan to enroll at least 15 more patients in the study.
Therapies with human stem cells for chronic venous leg ulcers ("open leg").
You can find the video summary HERE.
Source: German Dermatological Society e.V. (DDG) - https://derma.de/presse
RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘
For the press release click here
RHEACELL announces "First Patient In": EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected.
For the press release click here
Professor Dr. med. Karin Scharffetter-Kochanek, Dr. Christoph Ganss and Dr. Andreas Kluth from RHEACELL received the "Kooperationspreis Wissenschaft-Wirtschaft 2022" from Ulm University.
For the press release click here (only in German)
RHEACELL receives "Partners in Progress Award" from debra of America for Epidermolysis Bullosa research.
For the press release click here
It is only the second authorized "Somatic Cell Therapy Medicinal Product".
For more information click here
RHEACELL is conducting a follow-up study with highly purified stem cells for the treatment of previously incurable chronic ulcers.
For the press release click here
RHEACELL has been granted national marketing authorization in Germany (§ 4b of the German Medicinal Products Act) for its’ cell therapy product AMESANAR®, produced by TICEBA, for the use in patients with chronic wounds.
For the press release click here
The European Medicines Agency (EMA) has approved the pediatric investigation plan for our Epidermolysis Bullosa program, bringing us one step closer to filing for marketing authorization.
Based on convincing clinical results (I/IIa) in the indication of non-healing chronic venous ulcers (CVU), RHEACELL filed for national marketing authorization in Germany (special provisions governing advanced therapy medicinal products).
Heidelberg-based biopharmaceutical company demonstrates efficacy and safety of ABCB5-positive stem cells in CVU patients in clinical phase IIa trial.
Heidelberg-based biopharmaceutical company demonstrates safety and efficacy of ABCB5-positive stem cells in Phase IIa clinical trial.
Heidelberg-based biopharmaceutical company demonstrates safety and efficacy of ABCB5-positive stem cells in Phase IIa clinical trial.
Biopharma company completes three registered somatic cell therapy clinical trials for severe, chronic diseases.
The medicinal drug product tested in international phase I/IIa clinical trial has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
The medicinal drug product tested in international phase I/IIa clinical trial has been granted Orphan Drug Designation from the FDA and the European Medicines Agency) and Fast Track Designation from the FDA for the treatment of LSCD.
You will find more scientific papers by following this link.